Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals
Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in ... Read More
Mynosys Cellular Devices raises $25m from Decheng Capital
Mynosys Cellular Devices, which manufactures the Zepto cataract surgery device, has secured $25 million in a funding round led by investment firm Decheng Capital. The ... Read More
ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome
ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of ... Read More
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene ... Read More
Kodiak Sciences completes enrollment for KSI-301 safety study in retinal disease
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, ... Read More
Sun Pharmaceutical Industries gains FDA approval for CEQUA to treat dry eye disease
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in ... Read More